NFC
KERX

Northeast Financial Consultants’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Northeast Financial Consultants’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-46,100
Closed -$333K – 154
2017
Q2 		$333K Hold
46,100
– – 0.13% 110
2017
Q1 		$283K Hold
46,100
– – 0.12% 121
2016
Q4 		$270K Hold
46,100
– – 0.12% 120
2016
Q3 		$245K Hold
46,100
– – 0.1% 131
2016
Q2 		$305K Hold
46,100
– – 0.14% 113
2016
Q1 		$215K Hold
46,100
– – 0.11% 122
2015
Q4 		$233K Hold
46,100
– – 0.12% 109
2015
Q3 		$162K Hold
46,100
– – 0.08% 136
2015
Q2 		$460K Hold
46,100
– – 0.21% 88
2015
Q1 		$587K Hold
46,100
– – 0.27% 73
2014
Q4 		$652K Sell
46,100
-2,200
-5% -$34.1K 0.34% 63
2014
Q3 		$664K Hold
48,300
– – 0.36% 60
2014
Q2 		$742K Hold
48,300
– – 0.42% 55
2014
Q1 		$823K Sell
48,300
-3,700
-7% -$55.8K 0.48% 48
2013
Q4 		$673K Buy
+52,000
New +$621K 0.45% 42

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Northeast Financial Consultants's KERX Position: Q3 2017 in Review

Northeast Financial Consultants sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2017, closing a stake of 46,100 shares — an estimated $333K sold.

Northeast Financial Consultants first reported a position in KERX in Q4 2013 and held it in 15 quarters. The position peaked at $823K in Q1 2014. 132 funds tracked by Wall St. Rank hold KERX as of Q3 2017.

  • Northeast Financial Consultants reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
  • Northeast Financial Consultants sold 46,100 Keryx Biopharmaceuticals Inc shares in Q3 2017, an estimated $333K.
  • Northeast Financial Consultants first reported a position in Keryx Biopharmaceuticals Inc in Q4 2013 and held it in 15 quarters.
  • Northeast Financial Consultants's Keryx Biopharmaceuticals Inc position peaked at $823K in Q1 2014.
  • 132 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2017.

Based on Northeast Financial Consultants's 13F filing for Q3 2017, filed 13 Nov 2017.